New Serious Adverse Effects With Alemtuzumab in MS New Serious Adverse Effects With Alemtuzumab in MS

Several new and potentially life-threatening adverse events associated with the use of this novel agent for multiple sclerosis have been reported.Medscape Medical News
Source: Medscape Medical News Headlines - Category: Consumer Health News Tags: Neurology & Neurosurgery News Source Type: news

Related Links:

Elisabet Guillam ó, Álvaro Cobo-Calvo, Guillermo R. Oviedo, Noémie Travier, Juan Álamo, Oscar A. Niño-Mendez, Antonio Martínez-Yelamos, Sergio Martínez-Yelamos, Casimiro Javierre
Source: Journal of Sports Science and Medicine - Category: Sports Medicine Source Type: research
AbstractCladribine is a deoxyadenosine analogue prodrug that preferentially depletes lymphocytes, key cells underlying multiple sclerosis (MS) pathogenesis. Cladribine tablets (Mavenclad®) represent the first short-course oral disease-modifying drug (DMD) for use in MS. The tablets, administered in two short courses 1  year apart, are indicated for the treatment of adults with highly active relapsing MS on the basis of data from pivotal clinical trials, including the phase 3 study CLARITY and its extension. A cumulative cladribine tablets dose of 3.5 mg/kg administered in this fashion in CLARITY reduced clini...
Source: CNS Drugs - Category: Neurology Source Type: research
Publication date: Available online 13 August 2018Source: Multiple Sclerosis and Related DisordersAuthor(s): Barry A. HendinAbstractInterferon beta therapies have been effective in the treatment of relapsing forms of multiple sclerosis for over 2 decades. These therapies have varying routes and schedules of administration but broadly similar clinical and radiologic efficacy. The most commonly reported adverse effects are flu-like symptoms and injection site reactions. The most recent addition to the class is peginterferon beta-1a, which is administered subcutaneously every 2 weeks. Although clinically stable patients with m...
Source: Multiple Sclerosis and Related Disorders - Category: Neurology Source Type: research
ConclusionAdministrative data can be used to identify individuals with incident ON and TM, and to distinguish those with monophasic syndromes from those with an incident presentation of MS.
Source: Multiple Sclerosis and Related Disorders - Category: Neurology Source Type: research
Maria Blonda, Antonella Amoruso, Tommaso Martino, Carlo Avolio
Source: Frontiers in Neurology - Category: Neurology Source Type: research
Tumefactive demyelinating lesion (TDL) is often reported as a rare variation of multiple sclerosis (MS). TDL is difficult to diagnose solely by magnetic resonance imaging (MRI) in patients with no history of MS. This is because the lesion often shows ring enhancement with perifocal brain edema on gadolinium MRI, thus mimicking glioblastoma multiforme (GBM).
Source: World Neurosurgery - Category: Neurosurgery Authors: Tags: Case Report Source Type: research
Background Dimethyl fumarate (DMF) and fingolimod (FTY) are approved oral disease-modifying therapies for relapsing multiple sclerosis (MS). Observational studies are valuable when randomized clinical trials cannot be done due to ethical or practical reasons. Two-site studies allow investigators to further ascertain external validity of previously examined treatment effect differences. Limited head-to-head 2-site studies exist comparing DMF and FTY. Methods Patients prescribed DMF (n = 737) and FTY (n = 535) from 2 academic multiple sclerosis (MS) centers (Cleveland Clinic and University of Colorado) were identified. Disc...
Source: Neurology Clinical Practice - Category: Neurology Authors: Tags: Multiple sclerosis Research Source Type: research
Multiple sclerosis (MS) is one of the most frequently observed neurological conditions in Switzerland, but data sources for country-wide epidemiological trend monitoring are lacking. Moreover, while clinical a...
Source: BMC Neurology - Category: Neurology Authors: Tags: Study protocol Source Type: research
IJERPH, Vol. 15, Pages 1726: On the Nature of Evidence and ‘Proving’ Causality: Smoking and Lung Cancer vs. Sun Exposure, Vitamin D and Multiple Sclerosis International Journal of Environmental Research and Public Health doi: 10.3390/ijerph15081726 Authors: Robyn M. Lucas Rachael M. Rodney Harris If environmental exposures are shown to cause an adverse health outcome, reducing exposure should reduce the disease risk. Links between exposures and outcomes are typically based on ‘associations’ derived from observational studies, and causality may not be clear. Randomized controlled tr...
Source: International Journal of Environmental Research and Public Health - Category: Environmental Health Authors: Tags: Communication Source Type: research
Publication date: Available online 10 August 2018Source: NeuroImage: ClinicalAuthor(s): José María Mateos-Pérez, Mahsa Dadar, María Lacalle-Aurioles, Yasser Iturria-Medina, Yashar Zeighami, Alan C. EvansAbstractIn this paper, we provide an extensive overview of machine learning techniques applied to structural magnetic resonance imaging (MRI) data to obtain clinical classifiers. We specifically address practical problems commonly encountered in the literature, with the aim of helping researchers improve the application of these techniques in future works. Additionally, we survey how these algori...
Source: NeuroImage: Clinical - Category: Radiology Source Type: research
More News: Brain | Health | Multiple Sclerosis | Neurology | Neurosurgery